Amylin Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Amylin Pharmaceuticals
Private
Industry Biotechnology
Founded 1987
Headquarters San Diego, California, USA
Key people
Daniel M. Bradbury[1]
Products Symlin (pramlintide)
Byetta (exenatide)
Revenue IncreaseUS$758M (FY 2009)[2]
DecreaseUS$-173M (FY 2009)[2]
DecreaseUS$-186M (FY 2009)[2]
Total assets IncreaseUS$1.73B (FY 2009)[3]
Total equity IncreaseUS$423M (FY 2009)[3]
Number of employees
1,900 [1]
Slogan Challenging Science, Changing Lives.
Website www.amylin.com

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin,[4] as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.[5]

In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.[6]

In December 2013, Amylin was acquired by AstraZeneca.[7]

References[edit]

External links[edit]